Speciality: Hematology
Description:
A warm welcome to all the medical professionals to this session on "Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective." This session synthesizes the key takeaways from our discussion on ferric maltol, highlighting its transformative potential in the management of iron deficiency anemia (IDA). The overarching new perspective is a shift away from the traditional, one-size-fits-all approach to oral iron supplementation, toward a more nuanced and patient-focused strategy.
The primary limitation of standard oral iron salts is their high incidence of gastrointestinal (GI) side effects, which leads to poor patient adherence and treatment failure. Ferric maltol provides a new perspective by addressing this issue directly. Its unique chemical structure, a stable complex of ferric iron (Fe³⁺) and maltol, minimizes the release of free iron in the gut, thereby reducing GI irritation and inflammation. This improved tolerability is not just a secondary benefit; it is a core feature that can lead to better treatment compliance and, ultimately, more effective iron repletion.
In conclusion, the new perspective is that ferric maltol is not simply another oral iron option, but a clinically meaningful alternative that overcomes the historical drawbacks of traditional oral iron. Its proven efficacy and favorable tolerability profile, particularly in challenging patient populations like those with inflammatory bowel disease or chronic kidney disease, position it as a valuable tool in the modern management of IDA. This allows clinicians to choose a therapy that is both effective and well-tolerated from the outset, leading to a better quality of life for patients.
See More Webinars @ Hidoc Webinars
1.
Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
Interleukin-6 may boost prediction of obesity-related cancers
4.
Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.
5.
As EGFR internalization is decreased, BUB1 controls EGFR signaling.
1.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
2.
Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies
3.
HCC Codes in Oncology: Care Optimization in Plexiform Neurofibroma Management
4.
Unraveling the Mysteries of Coagulopathy: A Comprehensive Definition
5.
Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
5.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation